186 related articles for article (PubMed ID: 33116159)
1. Predictors of new-onset heart failure and overall survival in metastatic breast cancer patients treated with liposomal doxorubicin.
Szmit S; Grela-Wojewoda A; Talerczyk M; Kufel-Grabowska J; Streb J; Smok-Kalwat J; Iżycki D; Chmielowska E; Wilk M; Sosnowska-Pasiarska B
Sci Rep; 2020 Oct; 10(1):18481. PubMed ID: 33116159
[TBL] [Abstract][Full Text] [Related]
2. Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders.
Szmit S; Jurczak W; Zaucha JM; Długosz-Danecka M; Sosnowska-Pasiarska B; Chmielowska E; Joks M; Drozd-Sokołowska J; Knopińska-Posłuszny W; Spychałowicz W; Kumiega B; Charliński G; Morawska M; Słomian G
Int J Cardiol; 2017 May; 235():147-153. PubMed ID: 28268088
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE;
Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749
[TBL] [Abstract][Full Text] [Related]
5. [Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].
Szmit S; Filipiak KJ; Litwiniuk M; Opolski G; Wysocki P; Zaborska B; Krzakowski M
Kardiol Pol; 2016; 74(9):1031-6. PubMed ID: 27654476
[TBL] [Abstract][Full Text] [Related]
6. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
7. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
8. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.
Markman M
Expert Opin Pharmacother; 2006 Aug; 7(11):1469-74. PubMed ID: 16859430
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
11. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
Falandry C; Brain E; Bonnefoy M; Mefti F; Jovenin N; Rigal O; Guillem O; El Kouri C; Uwer L; Abadie-Lacourtoisie S; Cretin J; Jacquin JP; Paraiso D; Freyer G
Eur J Cancer; 2013 Sep; 49(13):2806-14. PubMed ID: 23735702
[TBL] [Abstract][Full Text] [Related]
12. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Alba E; Ruiz-Borrego M; Margelí M; Rodríguez-Lescure A; Sánchez-Rovira P; Ruiz A; Mel-Lorenzo JR; Ramos-Vázquez M; Ribelles N; Calvo E; Casado A; Márquez A; Vicente D; García-Sáenz JA; Martín M
Breast Cancer Res Treat; 2010 Jul; 122(1):169-76. PubMed ID: 20361253
[TBL] [Abstract][Full Text] [Related]
13. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
15. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.
Zhao M; Ding XF; Shen JY; Zhang XP; Ding XW; Xu B
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):15-26. PubMed ID: 28070993
[TBL] [Abstract][Full Text] [Related]
16. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
[TBL] [Abstract][Full Text] [Related]
17. Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission.
Mark M; Thürlimann B
Med Oncol; 2012 Sep; 29(3):1477-8. PubMed ID: 21667322
[No Abstract] [Full Text] [Related]
18. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
19. Renal toxicity with liposomal doxorubicin in metastatic breast cancer.
Yemm KE; Alwan LM; Malik AB; Salazar LG
J Oncol Pharm Pract; 2019 Oct; 25(7):1738-1742. PubMed ID: 30170515
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials.
Xing M; Yan F; Yu S; Shen P
PLoS One; 2015; 10(7):e0133569. PubMed ID: 26204517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
